• Katie E O'Sullivan, Susan Cull, Lara Armstrong, Aine McKendry, and GrahamAlastair N JANJDepartment of Cardiothoracic Surgery, Royal Victoria Hospital, Grosvenor Rd, 274 Grosvenor Road, Belfast, BT12 6BA, UK..
• Department of Cardiothoracic Surgery, Royal Victoria Hospital, Grosvenor Rd, 274 Grosvenor Road, Belfast, BT12 6BA, UK. kaosulli@me.com.
• Ir J Med Sci. 2022 Apr 1; 191 (2): 699-704.

BackgroundWe have entered an era of renewed interest in novel approaches to surgical intervention and minimally invasive and transcatheter technique. With an aging population, isolated tricuspid valve regurgitation incidence is rising; however, referral for surgical intervention remains low.AimsWe undertook this retrospective review to assess outcomes and challenges associated with tricuspid valve intervention.MethodsA comprehensive retrospective review of all patients undergoing tricuspid valve intervention in our institution between 2004 and 2018 was carried out.ResultsA total of 259 patients who underwent a tricuspid intervention between 2004 and 2018 were identified. Of those, 229 underwent a repair and 30 underwent a replacement. Median survival for repair was 3124 days, and replacement was 2294 days. In-patient mortality was 12% for those undergoing repair and 7% for the replacement patients. Of those undergoing redo tricuspid valve intervention, eight patients (61.5%) were alive at most recent follow-up. Eight patients required intraoperative pacemakers, 2 required postoperative pacemakers. Of those who had intraoperative epicardial pacing systems placed, 5 of the 8 remained pacing dependent on most recent follow up.ConclusionBeyond technical challenges, decision making regarding pacemaker requirement requires further exploration. Redo tricuspid valve surgery carries a significant mortality risk and consideration should be given to earlier intervention in this context.© 2021. Royal Academy of Medicine in Ireland.

18 keywords...

hide…